Serum Progesterone on the Day of Embryo Transfer and Pregnancy Rate.

Impact of Serum Progesterone Levels on the Day of Embryo Transfer in Artificial Endometrial Preparation Cycles on the Ongoing Pregnancy Rate.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03272412

Enrollment

1205

Registered

2017-09-05

Start date

2017-09-08

Completion date

2018-11-28

Last updated

2019-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ongoing Pregnancy Rate

Brief summary

This study aims to analyze whether serum Progsterone levels on the day of Embryo Transfer are related with Ongoing Pregnancy rate in artificial endometrial preparation cycles with intravaginal micronized progesterone.

Interventions

DIAGNOSTIC_TESTAnalysis of serum Progesterone in blood sample

Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

1. Age \<50 years old 2. Hormonal Replacement therapy cycle for embryo transfer in any of the following situations: 1. Embryos in fresh cycle with donated oocytes. 2. Subsequent embryo transfers of vitrified embryos in cycles of donated oocytes. 3. Frozen embryo transfers in cycles with autologous oocytes. 3. Endometrial line: \>6.5-7mm (with trilaminar aspect) in proliferative phase, before introducing progesterone. 4. Administration of natural micronized progesterone intravaginally (400 mg/12 hours for 5 complete days (10 dosis), before the embryo transfer and maintained until pregnancy week 12. 5. Embryo transfer of blastocyst (day 5-6). 6. Signed Informed Consent

Exclusion criteria

1. Uterine pathology (submucous o intramural fibroids (\>4 cm) or which deform the uterine cavity; endometrial polyps or Müllerian anomalies; or adnexal anomalies (communicating hydrosalpinx). 2. Simultaneous participation in another clinical study. 3. Participation in another clinical study before the inclusion in the present study, and which could affect the objectives of the present study.

Design outcomes

Primary

Measure	Time frame	Description
Concentration of serum Progesterone levels	The day of embryo transfer	Serum progesterone levels
Ongoing Pregnancies depending on Progesterone levels ranges.	Week 5-12 after Embryo Transfer	Ultrasound to confirm Ongoing Pregnancy

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026